✦ LIBER ✦

The scopolamine model as a pharmacodynamic marker in early drug development

✍ Scribed by Robert A. Lenz; Jeffrey D. Baker; Charles Locke; Lynne E. Rueter; Eric G. Mohler; Keith Wesnes; Walid Abi-Saab; Mario D. Saltarelli

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The use of pharmacokinetic and pharmacod

✍ D. K. Walker 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB

Experience and prospects with mechanisti

✍ J.-L. Steimer; B. Reigner; R. Gieschke; R. Xu; M.-O. Lemarechal; P. Francheteau; 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 129 KB

Systems Biology in Drug Discovery and De

✍ Young, Daniel L.; Michelson, Seth 📂 Article 📅 2011 🏛 John Wiley & Sons, Inc. ⚖ 131 KB

Pharmacokinetic-pharmacodynamic modeling

✍ Lemmens, Harry J M; Dyck, John B; Shafer, Steven L; Stanski, Donald R 📂 Article 📅 1994 🏛 Nature Publishing Group 🌐 English ⚖ 811 KB

[11C]Choline as pharmacodynamic marker f

✍ Bernd J. Krause; Michael Souvatzoglou; Ken Herrmann; Axel W. Weber; Tibor Schust 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 208 KB

Identifying Pharmacodynamic Protein Mark

✍ Patil, Sandeep T.; Higgs, Richard E.; Brandt, John E.; Knierman, Michael D.; Gel 📂 Article 📅 2007 🏛 American Chemical Society 🌐 English ⚖ 664 KB